Full-Time

Senior Assistant Administratif

Confirmed live in the last 24 hours

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

1,001-5,000 employees

Develops therapies for rare genetic diseases

No salary listed

Senior

Paris, France

This role typically requires that the majority of the work be conducted on-site.

Category
Administrative & Executive Assistance
Administrative Support
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • strong experience in pharma industry in France and knowledge of its regulation
  • Able to deliver to tight deadlines, comfortable with ambiguity, and shifting priorities
  • Strong organizational and planning skills in a fast-paced environment
  • Outstanding service mindset; Active listening skills with the ability to understand others’ perspectives, needs, or expectations
  • High attention to detail
  • Excellent organizational skills
  • Excellent interpersonal and communications skills, enjoying teamwork
  • Regularly works with time-sensitive and confidential information while exercising tact, diplomacy and discretion
  • Excellent computer skills (Word, Excel, PowerPoint, MS Office)
  • Fluent in French and English
Responsibilities
  • General administration & office management (mail processing, stationery, facility coordination, telephony)
  • Admin and infrastructure set up for new hires (employees and contractors)
  • Support administrative tasks coordination of the onboarding process for all new people in France & Benelux
  • Review, create and maintain sustainable office procedures, filing systems, reports and record keeping method
  • Generate contracts in Icertis
  • Manage POs and follow up with third party
  • Manage invoices follow up with accounting
  • Respond and manage requests from the team
  • Practical organization of network meetings (logistics, hotel and travel booking, organization of lunches / dinners)
  • Act as point of contact of field force: ensure that any event (RP, staff, local meeting) is implemented according to the LEA regulations; manage a follow-up file of events per area
  • Manage and follow the promotional material logistics (“dotation”) in close collaboration with the Field Force Manager, the General Manager and the Responsible Pharmacist
  • Management and monitoring of service providers
  • Partner with and support the communication agency in charge of congress logistics and symposia
  • Support the team with LEA follow up
  • Assist the Responsible Pharmacist in the preparation of spreadsheet for "transparency of links" declarations
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

View

Ultragenyx Pharmaceutical develops therapies for rare and ultra-rare genetic diseases, focusing on conditions with limited treatment options. The company has a diverse pipeline of clinical-stage programs, allowing it to address multiple rare diseases simultaneously. It stands out from competitors by having FDA-approved therapies, such as burosumab and UX007, which provide a revenue stream and validate its approach. Ultragenyx aims to ensure a continuous supply of its medicines to patients, even during challenges like the COVID-19 pandemic.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Novato, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • GTX-102 in Phase III trials could lead Ultragenyx in Angelman syndrome treatment.
  • NICE's recommendation of Evkeeza boosts Ultragenyx's market presence in the UK.
  • Setrusumab development opens new therapeutic avenues for bone formation treatments.

What critics are saying

  • Intense competition in Angelman syndrome treatment may impact Ultragenyx's market share.
  • Setrusumab's success is uncertain, facing potential clinical and regulatory challenges.
  • Delays in NICE's recommendation for Evkeeza could affect Ultragenyx's revenue.

What makes Ultragenyx Pharmaceutical unique

  • Ultragenyx focuses on rare and ultra-rare genetic diseases with limited treatment options.
  • The company has a diversified product pipeline addressing multiple rare diseases simultaneously.
  • Ultragenyx's commitment to uninterrupted medicine supply ensures consistent patient treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Volunteer Days

Stock Options

Company Equity

Wellness Program

Professional Development Budget

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Mar 17th, 2025
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx And Neuren

Several companies are working on new investigational treatments for Angelman syndrome, a rare genetic disorder that affects the nervous system and causes developmental delays, intellectual disability, seizures and speech impairment. Ionis and Ultragenyx are competing to bring investigational antisense oligonucleotide treatments to the market, while Neuren is betting on a synthetic peptide that can be delivered orally. It’s a tight race in a disease space with a high unmet need.Affecting 500,000 to 1 million patients worldwide, Angelman syndrome has no approved disease-modifying treatments. Although antiseizure medication is available, these drugs do not address the root cause, a genetic mutation in the UBE3A gene on chromosome 15. In Angelman syndrome, only the copy of the UBE3A gene inherited from the mother is functional, while the father’s allele is mutated.Both Ionis and Ultragenyx are currently in Phase III trials with their oligonucleotides, called ION582 and GTX-102, respectively. Meanwhile, Neuren is conducting a mid-stage trial on NNZ-2591, a twice-daily oral solution consisting of a synthetic peptide that modulates acetylcholine neurotransmission.Ionis’ ION582 is an investigational intrathecal injection that targets a long noncoding RNA to increase expression of the UBE3A protein in neurons

Arabic Week
Feb 20th, 2025
Global ANGPTL3-lowering therapy market is expected to reach US$ 785.21 million by 2031

Recent Developments In January 2024, Ultragenyx Pharmaceutical Inc. announced that the National Institute for Health and Care Excellence (NICE) has released a final draft guidance recommending Evkeeza (evinacumab) for use within NHS England.

GlobeNewswire
Jan 6th, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.

Stat News
Jan 6th, 2025
The biotech scorecard for the first quarter: 16 stock-moving events to watch

Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation.

TipRanks
Nov 5th, 2024
Ultragenyx Reports Strong Q3 Growth and Milestones

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, with a focus on advancing treatments where there are unmet medical needs.